ALK and non-small cell lung carcinoma: Currently, ROS1 rearrangements in NSCLC are treated with ALK inhibitors—crizotinib and entrectinib—based on the results from the PROFILE 1001 study (NCT00585195) for crizotinib and integrated analysis of the phase 2 STARTRK-2, phase 1 STARTRK-1, and the phase 1 ALKA-372-001 trials for entrectinib [34,35,36,37,38,39].